Correction of hyponatremia by tolvaptan before left ventricular assist device implantation

International Heart Journal

Volumn 53, Issue 6, 2012, Pages 391-393

  Imamura, Teruhiko ^a   Kinugawa, Koichiro ^a   Shiga, Taro ^a   Kato, Naoko ^a   Endo, Miyoko ^a   Inaba, Toshiro ^a   Maki, Hisataka ^a   Hatano, Masaru ^a   Yao, Atsushi ^a   Hirata, Yasunobu ^a   Nishimura, Takashi ^a   Kyo, Shunei ^a   Ono, Minoru ^a   Nagai, Ryozo ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Arginine vasopression; Heart failure; Osmotic demyelination syndrome

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; CATECHOLAMINE; DOBUTAMINE; ENALAPRIL; EPLERENONE; FUROSEMIDE; LOSARTAN; PIMOBENDAN; SODIUM; SPIRONOLACTONE; TOLVAPTAN; BENZAZEPINE DERIVATIVE;

ADULT; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CASE REPORT; CONGESTIVE CARDIOMYOPATHY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DOSE RESPONSE; HEART CATHETERIZATION; HEART FAILURE; HEART HEMODYNAMICS; HEART INDEX; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HUMAN; HYPONATREMIA; INTRAAORTIC BALLOON PUMP; LEFT VENTRICULAR ASSIST DEVICE; LOW DRUG DOSE; MALE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; SODIUM BLOOD LEVEL; URINE VOLUME; BLOOD; FOLLOW UP; HEART ASSIST DEVICE;

ADULT; BENZAZEPINES; FOLLOW-UP STUDIES; HEART FAILURE; HEART-ASSIST DEVICES; HUMANS; HYPONATREMIA; MALE; SODIUM;

EID: 84873722864     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.53.391     Document Type: Article

References (16)

1. Adrogué HJ, Madias NE. Hyponatremia. N Engl J Med 2000; 342: 1581-9. (Review)
2. Goldberg A, Hammerman H, Petcherski S, et al. Hyponatremia and long-term mortality in survivors of acute ST-elevation myocardial infarction. Arch Intern Med 2006; 166: 781-6.
3. Douglas I. Hyponatremia: why it matters, how it presents, how we can manage it. Cleve Clin J Med 2006; 73 Suppl 3: S4-12. (Review)
4. Leier CV, Dei Cas L, Metra M. Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: hyponatremia, hypokalemia, and hypomagnesemia. Am Heart J 1994; 128: 564-74. (Review)
5. Berl T. Treating hyponatremia: damned if we do and damned if we don't. Kidney Int 1990; 37: 1006-18. (Review)
6. Benedict CR, Johnstone DE, Weiner DH, et al. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators. J Am Coll Cardiol 1994; 23: 1410-20.
7. Costello-Boerrigter LC, Smith WB, Boerrigter G, et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol 2006; 290: F273-8.
8. Waikar SS, Mount DB, Curhan GC. Mortality after hospitalization with mild, moderate, and severe hyponatremia. Am J Med 2009; 122: 857-65.
9. Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med 2007; 120(11 Suppl 1): S1-21.
10. Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007; 297: 1319-31.
11. Udelson JE, Orlandi C, Ouyang J, et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol 2008; 52: 1540-5.
12. Gheorghiade M, Gottlieb SS, Udelson JE, et al. Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am J Cardiol 2006; 97: 1064-7.
13. Matsuzaki M, Hori M, Izumi T, Fukunami M. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther 2011; 25 Suppl 1: S33-45.
14. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355: 2099-112.
15. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol 2005; 46: 1785-91. (Review)
16. Udelson JE, McGrew FA, Flores E, et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol 2007; 49: 2151-9.